About Matinas BioPharma Holdings (NYSEAMERICAN:MTNB)
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections. Its cochleate delivery technology platform is designed for the targeted delivery of pharmaceuticals directly to the site of infection or inflammation. Its MAT 2203 is an oral formulation of a spectrum anti-fungal drug called amphotericin B, which uses its cochleate delivery technology. Its MAT2501 is an orally administered, encochleated formulation of the spectrum aminoglycoside antibiotic amikacin, which may be used to treat different types of multidrug-resistant bacteria, including non-tubercular mycobacterial infections (NTM), as well as various multidrug-resistant gram negative and intracellular bacterial infections.
Industry, Sector and Symbol:
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Sector: N/A
- Symbol: NYSEAMERICAN:MTNB
- CUSIP: N/A
- Web: www.matinasbiopharma.com
- Trailing EPS: ($0.44)
- Net Margins: -8,834.65%
- Return on Equity: -143.22%
- Return on Assets: -79.91%
- Outstanding Shares: 92,950,000
Frequently Asked Questions for Matinas BioPharma Holdings (NYSEAMERICAN:MTNB)
What is Matinas BioPharma Holdings' stock symbol?
Matinas BioPharma Holdings trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "MTNB."
How were Matinas BioPharma Holdings' earnings last quarter?
Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) issued its quarterly earnings results on Wednesday, November, 15th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.05) by $0.01. The firm had revenue of $0.05 million for the quarter, compared to analyst estimates of $0.05 million. Matinas BioPharma Holdings had a negative return on equity of 143.22% and a negative net margin of 8,834.65%. View Matinas BioPharma Holdings' Earnings History.
Where is Matinas BioPharma Holdings' stock going? Where will Matinas BioPharma Holdings' stock price be in 2017?
3 Wall Street analysts have issued 12-month target prices for Matinas BioPharma Holdings' stock. Their forecasts range from $6.00 to $9.00. On average, they expect Matinas BioPharma Holdings' stock price to reach $7.67 in the next year. View Analyst Ratings for Matinas BioPharma Holdings.
What are Wall Street analysts saying about Matinas BioPharma Holdings stock?
Here are some recent quotes from research analysts about Matinas BioPharma Holdings stock:
- 1. Maxim Group analysts commented, "Summary Matinas stock is down sharply today on news that MAT2203’s efficacy in VVC (vulvovaginal candidiasis) fell well below expectations both internal and external, but wait a second…Was it ever supposed to compare?." (6/26/2017)
- 2. Aegis analysts commented, "Matinas reported the results of the Phase I study testing safety, tolerability and pharmacokinetics of MAT2501, its cochleated version of amikacin. This announcement meets the endpoints and time frame we had expected. Separately, we have received inquiries regarding comments posted to a financial website to which we attribute the recent volatility in the stock. We believe these comments are based on incorrect information, and reiterate our Buy rating on the stock." (3/28/2017)
Are investors shorting Matinas BioPharma Holdings?
Matinas BioPharma Holdings saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 2,055,677 shares, an increase of 1.2% from the October 13th total of 2,032,088 shares. Based on an average daily trading volume, of 187,156 shares, the short-interest ratio is currently 11.0 days. Currently, 2.9% of the company's stock are sold short.
Who are some of Matinas BioPharma Holdings' key competitors?
Some companies that are related to Matinas BioPharma Holdings include Nabriva Therapeutics AG (NBRV), CASI Pharmaceuticals (CASI), Zynerba Pharmaceuticals (ZYNE), Palatin Technologies (PTN), OncoMed Pharmaceuticals (OMED), Pluristem Therapeutics (PSTI), Organovo Holdings (ONVO), Merrimack Pharmaceuticals (MACK), Curis (CRIS), Silence Therapeutics plc (SLN), Compugen (CGEN), Bioventix PLC (BVXP), Asterias Biotherapeutics (AST), Advaxis (ADXS), ArQule (ARQL), CTI BioPharma Corp. (CTIC), Oramed Pharmaceuticals (ORMP) and aTyr Pharma (LIFE).
Who are Matinas BioPharma Holdings' key executives?
Matinas BioPharma Holdings' management team includes the folowing people:
- Jerome D. Jabbour J.D., President (Age 42)
- Roelof Rongen, Chief Executive Officer, Director (Age 51)
- Gary Gaglione CPA, Vice President of Finance and Accounting and Acting Chief Financial Officer (Age 64)
- Douglas F. Kling, Senior Vice President - Clinical Development (Age 43)
- Abdel A. Fawzy Ph.D., Executive Vice President for Pharmaceutical and Supply Chain Development (Age 66)
- Dominick M. Dipaolo, Senior Vice President - Quality and Regulatory Compliance (Age 41)
- Raphael J. Mannino Ph.D., Chief Scientific Officer (Age 70)
- Herbert J. Conrad, Chairman of the Board (Age 84)
- Eric J. Ende M.D., Director (Age 48)
- Adam K. Stern, Director (Age 53)
Who owns Matinas BioPharma Holdings stock?
Matinas BioPharma Holdings' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Yellowstone Partners LLC (0.16%). Company insiders that own Matinas BioPharma Holdings stock include Adam K Stern, James S Scibetta and Roelof Rongen. View Institutional Ownership Trends for Matinas BioPharma Holdings.
Who bought Matinas BioPharma Holdings stock? Who is buying Matinas BioPharma Holdings stock?
Matinas BioPharma Holdings' stock was acquired by a variety of institutional investors in the last quarter, including Yellowstone Partners LLC. Company insiders that have bought Matinas BioPharma Holdings stock in the last two years include Adam K Stern, James S Scibetta and Roelof Rongen. View Insider Buying and Selling for Matinas BioPharma Holdings.
How do I buy Matinas BioPharma Holdings stock?
Shares of Matinas BioPharma Holdings can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Matinas BioPharma Holdings' stock price today?
One share of Matinas BioPharma Holdings stock can currently be purchased for approximately $1.19.
How big of a company is Matinas BioPharma Holdings?
Matinas BioPharma Holdings has a market capitalization of $112.50 million.
How can I contact Matinas BioPharma Holdings?
Matinas BioPharma Holdings' mailing address is SUITE 302, 1545 ROUTE 206 SOUTH, BEDMINSTER, NJ 7921, United States. The company can be reached via phone at +1-908-4431860.
MarketBeat Community Rating for Matinas BioPharma Holdings (NYSEAMERICAN MTNB)MarketBeat's community ratings are surveys of what our community members think about Matinas BioPharma Holdings and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Matinas BioPharma Holdings (NYSEAMERICAN:MTNB) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 3 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$7.67|
Consensus Price Target History for Matinas BioPharma Holdings (NYSEAMERICAN:MTNB)
Analysts' Ratings History for Matinas BioPharma Holdings (NYSEAMERICAN:MTNB)
(Data available from 11/21/2015 forward)
|8/10/2017||Roth Capital||Set Price Target||Buy||$9.00|
|8/8/2017||Maxim Group||Set Price Target||Buy||$6.00|
|3/28/2017||Aegis||Reiterated Rating||Buy -> Positive||$8.00|
Earnings History and Estimates Chart for Matinas BioPharma Holdings (NYSEAMERICAN:MTNB)
Earnings History by Quarter for Matinas BioPharma Holdings (NYSEAMERICAN MTNB)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/15/2017||Q3 2017||($0.05)||($0.04)||$0.05 million||$0.05 million||View||N/A|
|8/8/2017||Q2 2017||($0.05)||($0.04)||$0.02 million||$0.05 million||View||Listen|
|5/16/2017||Q1 2017||($0.04)||($0.25)||$0.02 million||View||N/A|
|11/10/2015||Q3 2016||($0.03)||($0.11)||$0.10 million||$0.06 million||View||N/A|
|8/13/2015||Q2 2015||($0.05)||($0.04)||$0.10 million||$0.08 million||View||N/A|
Earnings Estimates for Matinas BioPharma Holdings (NYSEAMERICAN:MTNB)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Matinas BioPharma Holdings (NYSEAMERICAN:MTNB)
No dividend announcements for this company have been tracked by MarketBeat.com
Latest Headlines for Matinas BioPharma Holdings (NYSEAMERICAN MTNB)
Matinas BioPharma Holdings (NYSEAMERICAN MTNB) Chart for Tuesday, November, 21, 2017